KEYNOTE-407 and KEYNOTE-189 trials demonstrated that the combination of pembrolizumab with platinum doublet chemotherapy led to OS benefit compared to chemotherapy alone in first-line treatment of NSCLC patients with untreated NSCLC, regardless of the PD-L1 status and the histological subtype (8, 9). The gene discussed is CD274; the disease is non-small cell lung carcinoma.